Eledon Pharmaceuticals (ELDN) Accumulated Expenses (2013 - 2026)

Eledon Pharmaceuticals' Accumulated Expenses history runs 14 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• Quarterly Accumulated Expenses rose 24.56% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 24.56% YoY) and the FY2025 annual result came in at $4.2 million, up 160.84% from the prior year.
• Accumulated Expenses was $1.6 million for Q1 2026 at Eledon Pharmaceuticals, down from $4.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $9.3 million in Q3 2025 and bottomed at $814000.0 in Q1 2022.
• A 5-year average of $2.7 million and a median of $2.0 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 535.94% — and 2024, when it plunged 56.78%.
• Eledon Pharmaceuticals' Accumulated Expenses stood at $3.9 million in 2022, then sank by 34.94% to $2.5 million in 2023, then plunged by 37.09% to $1.6 million in 2024, then surged by 160.84% to $4.2 million in 2025, then tumbled by 60.66% to $1.6 million in 2026.
• Business Quant data shows ELDN's Accumulated Expenses at $1.6 million in Q1 2026, $4.2 million in Q4 2025, and $9.3 million in Q3 2025.